People in the News

Dec 11, 2017

Wynemah Fuller

Wynemah Fuller has joined Aperiomics as director of operations. Previously, she worked in sales in the oil industry In Midland, Texas. She also started a US-wide online floral business.

Dec 11, 2017

Aimee Hoyt

Illumina has appointed Aimee Hoyt to senior vice president and chief people officer, where she will head the human resources team. Hoyt was previously chief people officer at Rackspace, a managed cloud company that was acquired by Apollo Global Management in 2016. She has also held senior positions at Hewlett-Packard, Cisco Systems, and Sun Microsystems. 

Dec 07, 2017

Aradhana Ghosh

Syapse has hired Aradhana Ghosh as vice president of oncology. In that role, she will lead the company's clinical operations. Ghosh, a medical oncologist, comes to Syapse from IBM Watson Health and had previously been a physician executive at McKesson. Ghosh earlier was medical director of specialty care for Santa Clara Health & Hospital System in California and was a physician champion for the enterprise-wide rollout of electronic health records at Kaiser Permanente. 

Dec 07, 2017

Frank Stokes

Castle Biosciences has appointed Frank Stokes as CFO, effective Dec. 4. He was most recently CFO of Hammock Pharmaceuticals and previous to that was a senior investment banker at Leerink. He also was at R.W. Baird and Wachovia Securities, now Wells Fargo Securities.

Dec 06, 2017

Ronald Moy

Ronald Moy has been appointed to DermTech's scientific advisory board. Moy is a past president of the American Academy of Dermatology, Pacific Dermatologic Association, and American Society for Dermatologic Surgery, as well as vice president of the Skin Cancer Foundation. 

Dec 06, 2017

Lori Batta

Lori Batta has been promoted to chief commercial officer of Celmatix. Previously, she was the company's senior vice president of sales. Prior to joining Celmatix, Batta was senior vice president of business development and strategic alliances at Good Start Genetics, and before that, she held senior roles at MDR Specialty Pharmacy, EMD Serono, and Novartis.

Dec 05, 2017

Barney Saunders

Purigen Biosystems has named Barney Saunders as its new CEO and a member of the board of directors. Saunders joins the Pleasanton, California-based nucleic acid sample prep firm from NanoString Technologies, where he served as SVP of sales and marketing, SVP and GM of life sciences, and chief commercial officer. He also previously served as chief commercial officer of Microchip Biotechnologies (which became IntegenX), and as a general manager at Agilent Technologies, where he led the team that launched the first commercially available full genome arrays for human, rat, and mouse.

Dec 04, 2017

Craig Venter

Human Longevity has reappointed Craig Venter as CEO, replacing Cynthia Collins who has served in the position for the past year. Saturnino Fanlo, who currently serves as HLI's CFO, has also been named chief operations officer. The company said it is streamlining to focus on its clinical research arm, Health Nucleus, for the early screening and detection of major diseases. 

Dec 04, 2017

Noah Nasser

Counsyl has appointed Noah Nasser to chief commercial officer. Nasser joined Counsyl last year, where he served as vice president of sales for women's health. Previously, he was senior vice president of sales at AltheaDx and was vice president of global sales and market development at Verinata Health, where he led his team through the firm's acquisition by Illumina in 2013. 

Dec 01, 2017

Eric Compton

Hologic has announced that its COO Eric Compton will leave at the end of December. Hologic appointed Compton as its COO in 2014. From 1995 to 2014, he worked at Johnson & Johnson in roles of increasing responsibility. For example, prior to joining Hologic, he served as the worldwide president of Ortho Clinical Diagnostics for Johnson & Johnson. 

Nov 29, 2017

Glen Weiss

Glen Weiss has been appointed chief medical officer of Circulogene. Prior to his appointment, he was director of clinical research and trials at the Cancer Treatment Centers of America. He holds a medical degree from the Sackler School of Medicine in Tel Aviv and an MBA from the W.P. Carey School of Business at Arizona State University.

Nov 29, 2017

Greg Hannon

Cancer Research UK and the University of Cambridge recently announced Greg Hannon as the new director of the Cancer Research UK Cambridge Institute. Hannon joined the Cancer Research UK Cambridge Institute in 2014 as a senior group leader. Prior to that he spent more than 20 years at Cold Spring Harbor Laboratory where he was a Howard Hughes Medical Institute Investigator and chaired the cancer genetics program as part of the Lab's National Cancer Institute-designated cancer center.

Nov 29, 2017

Jonathan Eisen

Zymo Research recently appointed Jonathan Eisen to its scientific advisory board. Eisen currently works at the University of California, Davis, where he holds appointments in the Department of Evolution and Ecology in the College of Biological Sciences and in the Department of Medical Microbiology and Immunology in the School of Medicine. He received his PhD in biology in 1998 from Stanford University, where he worked on the evolution of DNA repair. He has published more than 300 scientific articles and is a member of the American Academy of Microbiology.

Nov 28, 2017

Mark Dawson

Cambridge Epigenetix has named Mark Dawson to its scientific advisory board. Dawson is a professor in the Sir Peter MacCallum Department of Oncology and Centre for Cancer Research at the University of Melbourne, where he is the program head of the Translational Haematology Program, group leader of the Cancer Epigenetics Laboratory, and consultant hematologist in the Department of Hematology. His research is focused on epigenetic regulation in normal and malignant hematopoiesis and he is a leading expert on the development of targeted epigenetics-based therapeutics, Cambridge Epigenetix noted.

Nov 27, 2017

Thomas Widmann

Thomas Widmann has been appointed to the board of Cancer Genetics. He founded Actelion Pharmaceuticals and is a venture partner at Wellington Partners. Wildmann is also the founder of Hesperion, Widmann Associates, and Auraglobe. Before that he spent nine years at Hoffmann-La Roche where he led the international cardiovascular development department. 

Nov 27, 2017

Don Bailey

OncoCyte said in a document filed with the US Securities and Exchange Commission that Don Bailey has tendered his resignation from its board of directors. The firm will recruit a new independent director to fill his spot. No reason was given for his departure. Baily has been on OncoCyte's board since August. He was president and CEO of Questcor Pharmaceuticals from 2007 to 2014. From 1991 to 2000, he was CEO of Comarco, where he also served as its chairman of the board from 1998 to 2007. 

Nov 22, 2017

Humberto Huerta

MNG Laboratories earlier this month appointed Humberto Huerta as its senior director of business development. Most recently, Huerta held a commercial leadership role at Cynvenio Biosystems. Prior to that, he served in several positions at Ambry Genetics, including senior director of global development. In the past, he held sales and management positions at Ciba Corning, Beckman Instruments, Therakos, Oncotech, Siemens, and Cepheid.

Nov 22, 2017

Uta Francke, Val Sheffield, Kevin Campbell, Howard Worman, Benjamin Tycko

MNG Laboratories has added five members to its scientific advisory board. The new members are Uta Francke, professor emerita in the Department of Genetics at Stanford University School of Medicine; Val Sheffield, professor of pediatrics and ophthalmology and director of the Division of Medical Genetics at the University of Iowa Carver College of Medicine; Kevin Campbell, professor of neurology and internal medicine at the University of Iowa Carver College of Medicine; Howard Worman, professor of medicine and pathology and cell biology at Columbia University; and Benjamin Tycko, senior scientist in the Department of Biomedical Research at Hackensack University Medical Center.

Nov 20, 2017

Marc Eloit, Frederic Laurent, Olivier Lortholary, Robin Patel, Etienne Ruppé

PathoQuest has formed a scientific advisory board, comprising Marc Eloit, Frederic Laurent, Olivier Lortholary, Robin Patel, and Etienne Ruppé. Eloit is the founder of PatholQuest, a principal investigator at Institut Pasteur, and a professor of virology and former head of the virology unit at the Veterinary School of Maisons-Alfort. 

Laurent is a professor of microbiology at Hospices Civils de Lyon, while Lortholary is a professor and chair of the department of infectious and tropical diseases at  Hôpital Necker-Enfants Malades. Patel is chair of the division of clinical microbiology at the Mayo Clinic, and Ruppé is an assistant professor at the Hôpital Bichat. 

The SAB will advise PathoQuest on high-value medical applications for the firm's iDTECT Blood, an NGS-based metagenomic infectious disase diagnostic technology, it said. 

Nov 16, 2017

Emma Millican, Harold Swerdlow

LGC has appointed Emma Millican as global NGS business unit manager and Harold Swerdlow as head of NGS technology development, positions the firm created to support the launch of its new NGS business unit. 

Millican was previously director of scientific operations at the Wellcome Trust Sanger Institute and prior to joining the Sanger Institute, she was the UK director of forensic and applied genetics at Eurofins.

Swerdlow joins LGC from the New York Genome Center, where he was vice president of sequencing. Previously, he was head of research and development at the Wellcome Trust Sanger Institute and also served as chief technology officer at the Dolomite Center.

Nov 15, 2017

Mitch Levine

OncoCyte said that Mitch Levine has been appointed chief financial officer. Prior to joining OncoCyte, Levine was managing partner of Kirby Cover Capital Advisors, which provides consulting to international life sciences investment funds regarding US-based companies. In 2002 Levine founded Enable Capital Management. Prior to that, he was a founding member of The Shemano Group. He has also worked for Bear Stearns and Lehman Brothers.

Nov 14, 2017

Huntington Willard

Geisinger Health System has named Huntington Willard as director of the newly launched Geisinger National Precision Health Initiative, to be based near Washington, DC. Among his duties, Willard will oversee formation of a new precision health innovation lab. Willard, who was founding director of the Duke Institute for Genome Sciences & Policy and is a former president of the American Society of Human Genetics, will start in January. 

Nov 14, 2017

Samuel Riccitelli, David Cohen

Precipio has appointed Samuel Riccitelli as chairman, replacing Robert Patzig who resigned after seven years on the board of Transgenomic, which recently merged with Precipio. Also, David Cohen was elected as a new director at Precipio to fill an existing vacancy. 

Riccitelli has been on Precipio's board since June. From October 2012 through February 2017, he was president and CEO of Signal Genetics, where he also was a director. Before that, he was executive vice president and COO of Genoptix.

Cohen is COO and co-owner of Standard Oil of Connecticut, and has founded several ventures, including My Gene Counsel, a cancer bioinformatics company.

Nov 13, 2017

Chris Connelly, Brad Hunsley, Carissa Moore, Subodh Nimkar, John Scholl

Streck announced five new members of its leadership team: 

  • Chris Connelly, director of R&D for new product development/molecular. Connelly joined Streck in 2010 and was previously R&D scientific manager for the molecular division. 
  • Brad Hunsley, director of R&D for application development/existing products. Hunsley joined Streck in 1989, has held various leadership positions, and is currently a member of the company's scientific advisory committee.
  • Carissa Moore, director of R&D for new product development/stabilization and flow cytometry. Moore joined Streck in 2011 as an R&D scientist, and she served as R&D scientific manager from 2016 to 2017.
  • Subodh Nimkar, director of strategic marketing. Nimkar most recently served as a North America marketing programs manager at Agilent Technologies.
  • John Scholl, director of R&D for application development/private label products. Scholl joined Streck's R&D department in 1987 as a technician and was promoted to various supervisory positions in the department.
Nov 13, 2017

Annalisa Jenkins

PlaqueTec has appointed Annalisa Jenkins its CEO. She will lead the company's launch in 2018 of its biomarker-based PlaqueTec Liquid Biopsy System, which is being developed to improve risk assessment and enable earlier intervention in the management of coronary artery disease. The system collects biomarkers directly associated with plaques whtin coronary arteries in order to assess residual inflammatory risk. Jenkins formerly was the CEO of Dimension Therapeutics. Prior to that, she was Executive Vice President, Head of Global R&D for Merck Serono.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.